Maxim Jacobs
Maxim Jacobs is director of healthcare research, North America, for Edison Research. He joined Edison from Guidepoint Global, where he was a director of survey and tracker research, conducting extensive primary research across healthcare markets. He also brings more than 15 years of experience in equities to the healthcare team. Previously he was a senior healthcare analyst and therapeutic sector head at Ridgemark Capital and Broadfin Capital, and a healthcare analyst at Mehta Partners. Maxim is a CFA charter holder and graduated magna cum laude with a BA in Economics from the University of Pennsylvania.
Recent Quotes
"SNSS' SNS-062 is entering a Phase Ib/II dose escalation/expansion trial starting in Q2/17, targeting completion by September 2018."
—
Maxim Jacobs, Edison Investment Research
(6/15/17)
more >
"SNSS' SNS-062 Phase Ib/II is expected to begin in H1/17."
—
Maxim Jacobs, Edison Investment Research
(5/18/17)
more >
"SNSS has refocused its efforts squarely on SNS-062, which will now be the lead development program."
—
Maxim Jacobs, Edison Investment Research
(5/10/17)
more >
"SNSS' data from a Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile with twice a day dosing."
—
Maxim Jacobs, Edison Investment Research
(4/24/17)
more >
"Data from SNSS's SNS-062 Phase Ia study in healthy volunteers was recently presented and indicated an attractive PK/PD profile."
—
Maxim Jacobs, Edison Investment Research
(3/23/17)
more >
"SNSS' application for EU approval for vosaroxin in AML continues to progress"
—
Maxim Jacobs, Edison Investment Research
(3/15/17)
more >
"A phase 1b/2 study for SNSS' SNS-062 is expected to begin in H1/17."
—
Maxim Jacobs, Edison Investment Research
(2/16/17)
more >
"SNSS reported new data on SNS-062 and Qinprezo at the American Society of Hematology meeting in December 2016."
—
Maxim Jacobs, Edison Investment Research
(12/13/16)
more >
